Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 873M 778M 721M 655M 1.23B 82.74B 1.25B 8.64B 3.4B 43.25B 3.27B 3.21B 138B P/E 2026 *
14.9x
P/E 2027 * 12x
Enterprise Value 873M 778M 721M 655M 1.23B 82.74B 1.25B 8.64B 3.4B 43.25B 3.27B 3.21B 138B EV / Sales 2026 *
2.85x
EV / Sales 2027 * 2.34x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day+1.63%
1 week-4.28%
Current month-2.97%
1 month+0.17%
3 months+15.24%
6 months+44.06%
Current year+9.08%
1 week 45.48
Extreme 45.48
48.52
1 month 45.22
Extreme 45.22
50.49
Current year 24.95
Extreme 24.95
50.49
1 year 24.95
Extreme 24.95
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Compliance Officer 58 2022-11-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Exercice

Chief Financial Officer

9,200 0.0493%
9/1/26 Tax

Compliance Officer

-877 0.0047%
9/1/26 Tax

Chief Executive Officer

-2,424 0.0130%
Change 5-day change 1-year change 3-year change Capi.($)
+1.63%-4.28%+67.22%+411.16% 859M
-1.33%+4.88%+54.50%+109.94% 1,120B
-0.69%-3.77%+31.35%+66.62% 616B
-0.96%+0.55%+23.13%+94.26% 504B
+0.24%+5.58%+33.98%+59.40% 367B
-1.59%-1.25%+69.39%+43.02% 360B
-0.40%+3.53%+19.17%+46.55% 288B
-0.37%+3.35%-1.26%+16.85% 258B
-1.75%+1.76%+42.21%+51.44% 234B
-2.00%+1.75%+24.64%+95.14% 194B
Average -0.72%+2.35%+36.43%+99.44% 394.18B
Weighted average by Cap. -0.99%+3.52%+37.90%+75.50%

Financials

2026 *2027 *
Net sales 306M 273M 252M 230M 431M 28.99B 438M 3.03B 1.19B 15.15B 1.15B 1.12B 48.43B 373M 332M 308M 280M 525M 35.35B 534M 3.69B 1.45B 18.48B 1.4B 1.37B 59.06B
Net income 61.66M 54.96M 50.91M 46.29M 86.87M 5.85B 88.29M 611M 240M 3.06B 231M 226M 9.77B 81.45M 72.6M 67.25M 61.15M 115M 7.72B 117M 807M 317M 4.04B 306M 299M 12.9B
Net Debt - -
Projected Income Statement - Annual - Rigel Pharmaceuticals, Inc.
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-10-19 US$46.72 +1.63% 318,413
26-10-16 US$45.97 -2.71% 141,432
26-10-15 US$47.25 +0.92% 167,854
26-10-14 US$46.82 -0.68% 160,104
26-10-13 US$47.14 -3.42% 133,999
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rigel Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
46.72USD
Average target price
63.00USD
Spread / Average Target
+34.85%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rigel Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. RIGL Stock